# US 2025/0049737 A1 · Lauflumide and derivatives thereof for treating chronic fatigue syndrome and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049737 A1
- Document ID: US20250049737A1
- Status: Published application
- Kind: A1
- Application number: 18/576,881
- Filed: 2022-07-08
- Published: 2025-02-13
- Earliest claimed: 2021-07-08
- Assignees: NLS Pharmaceutics AG
- Applicants: NLS Pharmaceutics AG
- Inventors: Eric KONOFAL; Emily Samuela TURILLI
- Web page: https://patentgrep.com/patent/US20250049737A1

## CPC

- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention concerns a compound of formula (I), wherein R1=halogen atom selected in the group consisting of: F, Cl, Br, I, and R2=H or OH, or a pharmaceutically acceptable isomer, salt and/or solvate thereof, for use in preventing and/or treating chronic fatigue syndrome.

## Claims

### Claim at position 1

1-9. (canceled)

### Claim 10

A method of prevention and/or treatment of chronic fatigue syndrome comprising the administration of a compound of formula (I)
with R1=a halogen atom selected in the group consisting of F, Cl, Br, and I, and R2=H or OH,
or a pharmaceutically acceptable isomer, salt, and/or solvate thereof, to a patient in need thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the compound of formula (I) is
or a pharmaceutically acceptable isomer, salt, and/or solvate thereof.

### Claim 12 (depends on 10)

The method of claim 10, wherein a therapeutic dose of 50 mg/day to 500 mg/day is administered to the patient in need thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the therapeutic dose is 80 mg/day to 320 mg/day.

### Claim 14 (depends on 10)

The method of claim 10, wherein the chronic fatigue syndrome is a post-viral syndrome.

### Claim 15 (depends on 14)

The method of claim 14, wherein the chronic fatigue syndrome is a long COVID condition.

### Claim 16 (depends on 10)

A method of prevention and/or treatment of chronic fatigue syndrome comprising the administration of a pharmaceutical composition comprising a compound of formula (I) as defined in claim 10 or a pharmaceutically acceptable isomer, salt, and/or solvate thereof and a pharmaceutically acceptable excipient.

### Claim 17 (depends on 16)

The method of claim 16, wherein the compound of formula (I) is
or a pharmaceutically acceptable isomer, salt, and/or solvate thereof.

### Claim 18 (depends on 16)

The method of claim 16, wherein the chronic fatigue syndrome is a post-viral syndrome.

### Claim 19 (depends on 18)

The method of claim 18, wherein the chronic fatigue syndrome is a long COVID condition.

### Claim 20 (depends on 16)

The method of claim 16, wherein the pharmaceutical composition is suitable for oral or parenteral administration.

### Claim 21 (depends on 16)

The method of claim 16, wherein the pharmaceutical composition is in the form of a solution, a tablet, a capsule, or a Transdermal Delivery System.

### Claim 22 (depends on 16)

The method of claim 16, wherein the pharmaceutical composition is in the form of an injectable solution.
